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The vaccinia virus (VACV) complement control protein (VCP) is the major protein secreted from VACV-
infected cells. It has been reported that VCP binds to the surfaces of uninfected cells by interacting with
heparan sulfate proteoglycans (HSPGs). In this study, we show that VCP is also expressed on the surfaces of
infected cells and demonstrate that surface localization occurs independently of HSPGs. Since VCP does not
contain a transmembrane domain, we hypothesized that VCP interacts with a membrane protein that localizes
to the infected-cell surface. We show that the VACV A56 membrane protein is necessary for the cell surface
expression of VCP and demonstrate that VCP and A56 interact in VACV-infected cells. Since the surface
expression of VCP was abrogated by reducing agents, we examined the contribution of an unpaired cysteine
residue on VCP to VCP surface expression and VCP’s interaction with A56. To do this, we mutated the
unpaired cysteine in VCP and generated a recombinant virus expressing the altered form of VCP. Following
the infection of cells with the mutant virus, VCP was neither expressed on the cell surface nor able to interact
with A56. Importantly, the cell surface expression of VCP was found to protect infected cells from complement-
mediated lysis. Our findings suggest a new function for VCP that may be important for poxvirus pathogenesis
and impact immune responses to VACV-based vaccines.
The complement system is composed of30 soluble and cell
surface proteins that work in concert to protect the host from
invading pathogens (reviewed in references 46 and 47). Com-
plement can become activated by multiple pathways that con-
verge on the formation of a C3 convertase, the proteolytic
complex responsible for cleaving the central complement com-
ponent, C3. Cleavage of C3 results in the production of the
anaphylatoxin C3a and the opsonic fragment C3b. The gener-
ation of C3b results in the formation of a C5 convertase, the
proteolytic complex responsible for cleaving C5 into the C5a
anaphylatoxin and C5b. C5b, in turn, nucleates the formation
of a lytic pore called the membrane attack complex.
There is growing evidence that complement plays an impor-
tant role in protection against viral infection (9, 14–16, 20, 21,
23, 24, 27, 39, 43, 44). Complement activation can protect the
host against viruses by several mechanisms: (i) membrane at-
tack complex-induced lysis of virus particles or infected cells;
(ii) opsonization by C3b, which neutralizes virus infectivity and
enhances immune recognition; and (iii) enhancement of hu-
moral and cellular immune responses (4). In response to the
antiviral effects of complement, many viruses have developed
methods to evade complement activation, primarily by produc-
ing complement-regulatory proteins or incorporating host-de-
rived complement-regulatory proteins into the viral envelope
(4, 8, 10, 11, 14, 17, 35, 42).
Orthopoxviruses encode complement control proteins that
share a high degree of similarity with mammalian complement-
regulatory proteins (18). The vaccinia virus (VACV) comple-
ment control protein (VCP) is the most thoroughly studied
poxvirus complement-regulatory protein. It is homologous to
the smallpox inhibitor of complement enzymes (SPICE) en-
coded by variola virus and to the monkeypox inhibitor of com-
plement enzymes (MoPICE) (19, 33, 36, 41). VCP and SPICE
inhibit the activation of the classical and alternative comple-
ment pathways by accelerating the irreversible decay of C3 and
C5 convertases and by functioning as cofactors for the factor
I-mediated cleavage and inactivation of C3b and C4b (3, 17,
22, 26, 32–34, 36). MoPICE has cofactor activity but differs
from VCP and SPICE in that it lacks decay-accelerating activ-
ity (19). VCP, SPICE, and MoPICE also contain an unpaired
cysteine residue that allows each protein to dimerize, which
enhances its complement-regulatory function in vitro (19).
Although VCP has been characterized almost exclusively as
a soluble protein that is secreted from infected cells (17), it has
also been reported that recombinant VCP can attach to the
surfaces of uninfected cells by interacting with heparan sulfate
proteoglycans (HSPGs) (38). In this paper, we show that VCP
is expressed on the surfaces of infected cells in an HSPG-
independent fashion. This process is instead dependent on an
interaction between VCP and another viral protein, A56. We
show that the ability of VCP to interact with A56 and localize
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to the cell surface requires an unpaired cysteine residue on
VCP. Importantly, the expression of VCP on the cell surface
protects infected cells from complement-mediated lysis.
MATERIALS AND METHODS
Cells and infections. BSC-1 and RK-13 cells were grown in minimal essen-
tial medium (MEM). L929, Gro2C, and STO cells were grown in high-glucose
Dulbecco’s modified eagle medium. Medium was supplemented with antibi-
otic-antimycotic (Invitrogen) and 10% fetal bovine serum (FBS). Infections
were carried out in growth medium containing 2.5% FBS unless otherwise
indicated.
Recombinant viruses. Table 1 summarizes the recombinant viruses con-
structed for this study. VACV with wild-type VCP, mutant VCP, and VCP
knocked out (vv-VCPwt, vv-VCPmut, and vv-VCPko, respectively) were gener-
ated by homologous recombination of plasmid constructs into the parental virus
vSIGK-3 (17). This parental virus has a gpt selection cassette inserted within the
VCP open reading frame (ORF). Recombinant viruses were then isolated by
reverse gpt selection (13). After three rounds of plaque purification, isolated
plaques were expanded and recombinant viruses were analyzed by PCR and
Western blotting to confirm the construct. vv-VCPwt was generated using the
plasmid pGK35 (13), a pUC plasmid with the 1-kbp HincII-HincII fragment of
genomic DNA containing the VCP ORF. This plasmid also served as the tem-
plate for generating the cysteine-to-threonine mutation in VCP. Mutation of
VCP was achieved using the QuikChange site-directed mutagenesis kit (Strat-
agene) and the primers listed in Table 1 for vv-VCPmut. The mutagenized
plasmid was sequenced to confirm the introduction of the N-terminal cysteine
mutation and to ensure that no other mutations were introduced during PCR
amplification. Complete deletion of the VCP ORF was achieved by constructing
a plasmid containing only the right and left flanking regions of the VCP ORF.
This was accomplished by a partial digestion of pSI89, a pUC plasmid with the
3-kbp HindIII-EcoRI fragment of the HindIIIC genomic DNA, with HincII to
remove 1.5-kbp fragments containing the entire VCP ORF as well as some
flanking sequence. The missing left and right flanking regions were then rein-
troduced into the plasmid by the ligation of PCR products generated with the
primers and the common restriction site indicated in Table 1 for vv-VCPko.
vv-VCPwt-His and vv-VCPmut-His were designed to overexpress His-tagged
forms of VCPwt and VCPmut, respectively. The viruses were generated by
homologous recombination of plasmid constructs into the parental virus
vSIGK-1 (17). This parental virus has a gpt selection cassette replacing the entire
VCP ORF (as well as a portion of the flanking regions). His-tagged forms of
VCP under the control of a VACV synthetic strong early-late promoter (7) were
then inserted into the thymidine kinase locus, and recombinant viruses were
isolated by selection with bromodeoxyuridine and screening with -galactosi-
dase. After three rounds of plaque purification, isolated plaques were expanded
and the sequences of the recombinant viruses were confirmed using PCR and
Western blotting. The plasmids used for homologous recombination were con-
structed by adding a 7-His tag to the carboxy terminus of the VCP ORF using
the PCR primers listed in Table 1 for vv-VCPwt-His and by cloning this PCR
product into pSC65 (7). The resulting plasmid also served as the template to
generate a His-tagged VCP containing the cysteine-to-threonine mutation. This
mutation was introduced using QuikChange site-directed mutagenesis (Stra-
tagene) with the same primers used for vv-VCPmut (Table 1). Plasmids were
sequenced to confirm the mutation and to ensure that no other unintended
mutations were generated during PCR amplification.
Viruses with deletions in the A56R and K2L ORFs were constructed by
replacing the ORFs with the genes for -glucuronidase (GUS) or yellow fluo-
rescent protein (YFP), respectively. Recombinant viruses were generated by
homologous recombination of plasmid constructs into a wild-type VACV, strain
WR. Recombinant viruses were then isolated by screening for marker expres-
sion. After three rounds of plaque purification, isolated plaques were expanded
and the sequences of recombinant viruses were confirmed by PCR and Western
blotting or their syncytium-inducing phenotype was confirmed in BSC cells. To
generate the plasmid to delete the A56 ORF, the flanking regions of A56 were
recreated using the primers listed in Table 1 and cloned into pUC19. These
primers also introduce a common restriction site (PstI) between the right and left
flanks. The resulting plasmid was then digested with PstI to insert a GUS
expression cassette driven by a VACV promoter (6). The plasmid used to delete
the K2L ORF was constructed in a similar fashion using the primers listed for
vv-K2ko, except that a YFP expression cassette driven by a VACV promoter was
inserted into the K2 ORF.
IF. Confluent monolayers of BSC-1 or RK-13 cells seeded in eight-well cham-
ber slides (Nunc) were infected overnight with 1 PFU/cell of the viruses indicated
in the figures. For surface staining, infected cells were washed with phosphate-
buffered saline (PBS) and fixed with 2% paraformaldehyde dissolved in PBS. For
intracellular staining, cells were washed, fixed, and permeabilized with 0.1%
Triton X-100. Cells were then blocked in 1% FBS in PBS and subsequently
incubated for 1 h at room temperature with 10 g/ml of a mouse anti-VCP
monoclonal antibody (MAb), 3F11 (12). Cells were washed three times, and the
anti-VCP antibody was detected using a secondary anti-mouse immunoglobulin
G (IgG) antibody conjugated to either fluorescein isothiocyanate (FITC; Zymed)
or Alexa 546 (Molecular Probes), as indicated below. Cells were incubated in
secondary antibody at a dilution of 1:200 for 1 h at room temperature and then
washed three times with PBS. Coverslips were mounted on slides using mounting
medium containing DAPI (4,6-diamidino-2-phenylindole; Vector Laboratories)
to stain the nuclei, and the slides were examined using a Nikon Eclipse E1000
immunofluorescence (IF) microscope.
For confocal microscopy, cells were infected and processed as described
above. The anti-VCP MAb (3F11) was detected using a goat-anti mouse IgG
secondary antibody conjugated to allophycocyanin (Biolegend). A56 was de-
tected using polyclonal antisera raised against recombinant A56 (generously
provided by Bernard Moss) and a goat anti-rabbit IgG secondary antibody
conjugated to FITC (Zymed). Slides were examined using a Nikon TE2000-U
inverted microscope coupled to a PerkinElmer confocal imaging system.
Flow cytometry. BSC-1, L929, and Gro2C cells were infected overnight at a
multiplicity of infection (MOI) of 1. The next day, the medium was removed and
cells were washed with PBS and lifted with PBS containing 0.5 mM EDTA. For
surface staining, cells were washed once in FACS buffer (PBS with 2% bovine
serum albumin and 0.04% NaN3). For intracellular staining, cells were perme-
abilized using Cytofix/CytoPerm (BD) as per the manufacturer’s instructions and
washed twice with PermWash buffer (BD). Cells were then incubated with 0.4
g/sample of the anti-VCP MAb 3F11 (12) for 30 min at room temperature.
After being washed, cells were incubated with 1 l of a phycoerythrin-conjugated
anti-mouse IgG antibody (Biolegend)/sample. Cells were washed, fixed in 2%
paraformaldehyde, and collected using a FACSCalibur (BD). Data were ana-
lyzed using FlowJo software (Treestar). Dead cells were excluded from the
analysis gate based on forward-scatter and side-scatter profiles.
Heparin competition. BSC-1 cells were infected at an MOI of 1 overnight in
2.5% growth medium. Medium was aspirated and cells were washed once with
fresh medium. Soluble heparin (Sigma) was then added to the cells at the
concentrations indicated in Fig. 1 and incubated for 2 h at 37°C; afterwards, the
cells were washed two times and lifted with 0.5 mM EDTA in PBS. VCP
expression was analyzed using flow cytometry as described above.
Western blotting. BSC-1 cells were infected overnight at an MOI of 1 in
serum-free Opti-MEM. Supernatant from infected cells was collected and cen-
trifuged to remove cells and cellular debris. The supernatant was then concen-
trated using a Centricon centrifugal filter (Millipore) with a 30-kDa-protein
cutoff. The remaining infected cells were lysed using cell lysis buffer (Promega)
containing a 1 protease inhibitor cocktail (Sigma). Proteins were boiled in
sample buffer containing 1% sodium dodecyl sulfate (SDS) and 2-mercaptoeth-
anol, resolved on a 10% precast Tris-glycine polyacrylamide gel (Invitrogen),
transferred to nitrocellulose, and incubated overnight in blocking buffer (PBS,
5% milk, and 0.02% Tween 20). For nonreducing, nondenaturing (native) gels,
cells were infected in 2.5% MEM and cell lysates were harvested as described
above and lysed in RIPA buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris)
containing 1 protease inhibitor (Sigma). Native samples were diluted in sample
buffer containing 0.1% SDS, and proteins were resolved on a 10% Tris-glycine
gel and Western blotted for VCP.
For reducing and denaturing gels, membranes were probed for VCP using
the mouse anti-VCP MAb 5F1 (12) at a concentration of 5 g/ml in blocking
buffer for 2 h at room temperature. Native VCP was detected using the mouse
anti-VCP MAb 3F11 (12) at a concentration of 5 g/ml. After being washed
with PBS containing 0.02% Tween 20, horseradish peroxidase-conjugated
goat anti-mouse secondary antibody (Santa Cruz) was diluted 1:2,000 in
blocking buffer and incubated with the membranes for 2 h. The membranes
were then washed, and proteins were detected by chemiluminescence using
the enhanced-chemiluminescence Western blotting detection kit (GE Health-
care Biosciences). Blots were imaged using an LAS-1000 Pus gel documen-
tation system (Fujifilm).
A56 pulldown. BSC-1 cells were infected in 2.5% MEM at an MOI of 1 for
48 h. Cells were harvested, washed once in ice-cold buffer (50 mM Tris-HCl [pH
7.4] and 150 mM NaCl), and lysed in lysis buffer (50 mM Tris-HCl [pH 7.4], 1%
Triton X-100, 150 mM NaCl, and 1 protease inhibitor cocktail [Sigma]). Cells
lysates were clarified by centrifugation and incubated with nickel-agarose beads
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TABLE 1. Summary of the recombinant viruses constructed for this study
Name used
herein
Laboratory
reference
Parental
virus Description
Primer
name Primer description Primer sequence Additional information
vv-VCPwt vKSNG-181 vSIGK-3 Wild-type VCP ORF
reinserted into the gpt
deletion virus
vv-VCPmut vKSNG-182 vSIGK-3 Cysteine mutation of the
VCP ORF reinserted
into the gpt deletion
virus
olKV-160 Forward primer for
QuikChange
mutagenesis of
cysteine to
threonine
5-GGGAATAGGAT
GCGTTCTATCAA
CATGTACTATTCC
GTCACGACCC-3
Mutated codon is
underlined
olKV-161 Reverse primer for
QuikChange
mutagenesis of
cysteine to
threonine
5-GGGTCGTGACG
GAATAGTACATG
TTGATAGAACGC
ATCCTATTCCC-3
Mutated codon is
underlined
vv-VCPko vYXSI-179 vSIGK-3 Complete deletion of
the VCP ORF
reinserted into the gpt
deletion virus
olSI-53 Forward primer to
recreate right flank
of VCP
5-CTTGTGTTAACG
ATGGAAAGTTAT
ATGTAATAGG-3
HpaI site is underlined
olSI-54 Reverse primer to
recreate right flank
of VCP
5-AAGGAAAAAGC
GGCCGCATAAAA
AGCCCCCATATA
TGTTCGC-5
NotI site is underlined
olSI-55 Forward primer to
recreate left flank
of VCP
5-TTTTCCTTTTGCG
GCCGCATAAAAC
ATAAAAATTATA
CAATGG-3
NotI site is underlined
olSI-56 Reverse primer to
recreate left flank
of VCP
5-GCCAAGTTGACC
AATTCATTTCTAA
TAG-3
HincII site is
underlined
vv-VCPwt-His vSIJC-20 vSIGK-1 Overexpression of VCP-
His (using pSC-65)
inserted into the tk
locus of vSIGK-1
olSI-59 Forward primer to
generate VCP
5-ACGCGTCGACAT
GAAGGTGGAGA
GCGTGACG-3
SalI site is underlined;
initiating ATG
codon is in bold
olSI-60 Reverse primer that
attaches 7-His tag
on the carboxy
terminus of VCP
5-TCCCCCGGGTCT
AGATTAGTGATG
GTGATGGTGGTG
ATGCATGCGTAC
ACATTTTGGAAG
TTCCG-3
SmaI site is
underlined; XbaI
site is in italics; new
stop codon is in bold
vv-VCPmut-His vBDSI-205 vSIGK-1 Overexpression of the olKV-160 See the sequence for
cysteine mutation of olKV-161 olKV-160 above
VCP-His (using pSC-
65) inserted into the
tk locus of vSIGK-1
See the sequence for
olKV-161 above
vvA56ko vXF186 WR Full deletion of the
A56R ORF with
insertion of the GUS
cassette
olXF-156 Forward primer of
the left flank of the
A56R ORF
5-TCAGAAGATGGA
TGGATGAAGCAT
C-3
PCR product was cut
with a naturally
occurring SalI site
within the PCR
product
olXF-157 Reverse primer of the
left flank of the
A56R ORF
5-AACTGCAGGGTG
TAGCGTATACTA
ATGATATT-3
PstI site is underlined
olXF-158 Forward primer of
the right flank of
the A56R ORF
5-AACTGCAGAATT
ATATTGTCGGCC
GTGGC-3
PstI site is underlined
olXF-159 Reverse primer of the
right flank of the
A56R ORF
5-CTACAACGAAGC
TTGGTCTCAAC
C-3
HindIII site is
underlined
vvK2ko vXFAD189 WR Full deletion of the K2L
ORF with insertion of
the YFP cassette
olXF-152 Forward primer of
the left flank of the
K2L ORF
5-CACCGGATGATG
GATTAGGTCTT
C-3
PCR product was cut
with a naturally
occurring EcoRI site
within the PCR
product
olXF-153 Reverse primer of the
left flank of the
K2L ORF
5-GGGGTACCATTA
TTGATGTCTACA
CATCC-3
KpnI site is underlined
olXF-154 Forward primer of
the right flank of
the K2L ORF
5-GGGGTACCTATG
GGTACGGTGTAA
GGAATC-3
KpnI site is underlined
olXF-155 Reverse primer of the
right flank of the
K2L ORF
5-AACTGCAGGCAT
GTTACCACTATC
AACCG-3
PstI site is underlined
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for 2 h at 4°C. Samples were loaded onto a column, washed three times with lysis
buffer containing 20 mM imidazole, and eluted with lysis buffer containing 500
mM imidazole. Proteins eluted from the column were separated by SDS-poly-
acrylamide gel electrophoresis (PAGE) under reducing and denaturing condi-
tions and transferred to nitrocellulose. Membranes were probed for His-tagged
VCP and for A56. To probe for His-tagged VCP, membranes were incubated
with a primary anti-His tag MAb (Qiagen) diluted 1:200. The membrane was
then washed and incubated with a horseradish peroxidase-conjugated secondary
goat anti-mouse IgG antibody diluted 1:3,000 (Santa Cruz). Membranes were
also probed for A56 using polyclonal rabbit anti-A56 peptide antiserum (gener-
ous gift from Bernard Moss) diluted 1:1,250. The membranes were then washed
and incubated with a secondary donkey anti-rabbit antibody conjugated to horse-
radish peroxidase (GE Healthcare Biosciences). Proteins were detected with
SuperSignal West Pico chemiluminescence reagent and imaged using an LAS-
1000 Pus gel documentation system (Fujifilm).
Complement lysis assay. L929 cells infected overnight at an MOI of 1 were
washed twice with PBS containing 1% FBS, lifted with 0.5 mM EDTA in PBS,
and counted. To activate the classical pathway, 5  105 infected cells were
incubated for 1 h at room temperature with 50 g/ml of a polyclonal rabbit
anti-VACV antibody (Virostat) that binds to infected cells (our unpublished
observation). Cells were washed once and incubated with 25% guinea pig com-
plement serum (Sigma) diluted in gelatin barbital (Veronal)-buffered saline
containing Ca2 and Mg2 (Sigma) for 45 min at 37°C. Cells were then washed
twice, and viability was assessed using a fixable amine-reactive viability dye
(Invitrogen). This dye penetrates damaged cell membranes and reacts with
amine groups in the cytoplasm, resulting in an increase in the fluorescence
intensity of damaged cells (31). The percentage of cells with increased fluores-
cence was determined by using Overton subtraction (28) to compare populations
treated with antibody and complement to those treated with antibody alone.
Statistical significance was determined using Student’s t test.
RESULTS
VCP is expressed on the surfaces of infected cells. Purified
recombinant VCP has been reported to attach to the surfaces
of uninfected cells by interacting with HSPGs (38), but the
binding of VCP to cells during VACV infection has not been
examined. To determine if VCP attaches to the surfaces of
infected cells, we infected BSC-1 cells and examined the cell
surface expression of VCP using IF. Staining of nonpermeabi-
lized cells infected with the wild-type virus, vv-VCPwt, re-
vealed that VCP is expressed on the surfaces of infected cells
(Fig. 1A). In contrast, no staining was observed following in-
fection with a recombinant virus with a deletion in the gene
encoding VCP, vv-VCPko (Fig. 1A). Cell surface staining of
VCP was confirmed by confocal microscopy (data not shown).
Since the binding of recombinant VCP to the surfaces of
uninfected cells has been attributed to its interaction with
HSPGs (38), we asked whether the surface expression of VCP
during infection was also dependent on HSPGs. To address
this question, we infected wild-type L929 cells and an L929-
derived heparan-deficient cell line, Gro2C (1). Ninety-three
percent of L929 cells and 96% of Gro2C cells expressed VCP
with mean fluorescence intensities (MFI) of 370 and 400, re-
spectively (Fig. 1B). These results indicate that VCP expres-
sion on the surfaces of infected cells was independent of hepa-
FIG. 1. Expression of VCP on the surfaces of infected cells occurs independently of HSPGs. (A) BSC-1 cells were infected overnight with
vv-VCPwt (VCPwt) or vv-VCPko (VCPko), and the surface expression of VCP (green) was examined using IF by staining nonpermeabilized cells
with MAb 3F11 (10 g/ml). Nuclei were counterstained with DAPI (blue). (B) L929 (HSPG-positive) or Gro2C (HSPG-negative) cells were
infected overnight with vv-VCPko or vv-VCPwt, and the surface expression of VCP was examined on nonpermeabilized cells by staining them with
MAb 3F11 using flow cytometry. Gates (dashed line) were drawn such that 1% of cells in the VCPko population are positive (MFI  66).
Ninety-three percent of L929 cells were VCP positive, with an MFI of 370; 96% of Gro2C cells were positive, with an MFI of 400. (C) BSC-1 cells
were infected overnight at an MOI of 1 with vv-VCPko and vv-VCPwt and then treated with soluble heparin at the indicated concentrations for
2 h prior to being stained for VCP. Numbers indicate the percentages of VCP-positive cells. The numbers in parentheses are MFI. Results are
representative of several independent experiments.
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ran sulfate (Fig. 1B). To further validate that the cell surface
expression of VCP on infected cells was not dependent on
HSPGs, we performed a competition experiment to determine
if soluble heparin, an analog of HSPG, could remove VCP
from the surfaces of infected cells, as has been demonstrated
for other heparin-binding proteins (2). BSC-1 cells were in-
fected overnight and then incubated for 2 hours in the pres-
ence of soluble heparin prior to being stained for VCP. We
found that concentrations of heparin up to 500 g/ml affected
neither the percentage of cells expressing VCP on the surface
nor the MFI of VCP staining (Fig. 1C). Even at 500 g/ml of
heparin, 82% of cells were positive for VCP, with an MFI of
44, while 87% of untreated cells were positive, with an MFI
of 57 (Fig. 1C). These results suggest that the majority of VCP
expressed on the cell surface during infection attaches inde-
pendently of HSPGs.
The expression of VCP on the cell surface requires an un-
paired cysteine residue. To understand how VCP is expressed
on the cell surface during infection, we treated infected cells
with various buffers to see if we could dissociate VCP from the
cell surface. Interestingly, buffers containing the reducing
agents 2-mercaptoethanol or dithiothreitol abrogated the cell
surface staining of VCP but did not affect the surface staining
of a virus-encoded transmembrane protein, B5 (data not
shown). Based on this finding, we hypothesized that disulfide
bond formation is important for localizing VCP to the cell
surface during infection. To address this hypothesis, we mu-
tated the N-terminal unpaired cysteine on VCP to a threonine
residue using site-directed mutagenesis and generated a re-
combinant virus expressing this altered form of VCP (vv-
VCPmut). Western blot analysis of lysates and supernatants
from BSC-1 cells infected with vv-VCPwt and vv-VCPmut con-
firmed that VCPmut is expressed in and secreted from infected
cells, indicating that mutating the unpaired cysteine residue
did not affect protein expression (Fig. 2A). However, when
cells infected with vv-VCPmut were surface stained for VCP,
VCP was not detected on the surfaces of nonpermeabilized
cells, as measured by flow cytometry and IF (Fig. 2B and C).
However, VCP was still detected in permeabilized cells (Fig.
2B and C), confirming that mutating the cysteine residue did
not affect protein expression. Taken together, these results
show that mutation of the unpaired cysteine residue on VCP
abrogates surface expression, without affecting the production
or secretion of this protein.
FIG. 2. Cell surface expression of VCP requires an unpaired cysteine residue. (A) BSC-1 cells were infected overnight with vv-VCPko,
vv-VCPwt, or vv-VCPmut, a virus that expresses VCP with its N-terminal unpaired cysteine residue mutated to a threonine. Cell lysate and
supernatant from infected cells were resolved using SDS-PAGE and Western blotted for VCP using MAb 5F1 at a concentration of 5 g/ml.
(B) BSC-1 cells were infected overnight with the indicated viruses, and the expression of VCP was examined on the cell surfaces of nonperme-
abilized cells and within permeabilized cells using flow cytometry. Infected cells were washed and lifted with PBS–0.5 mM EDTA. For surface
staining, cells were washed with FACS buffer and stained for VCP. For intracellular staining, cells were permeabilized using Cytofix/Cytoperm
(BD) prior to being stained for VCP. Gates (dashed lines) were drawn such that 1% of cells in the VCPko population are positive. For
nonpermeabilized cells, 78% of cells infected with vv-VCPwt are positive for VCP, with an MFI of 141, while 1.5% of cells infected with vv-VCPmut
are positive, with an MFI of 16. For permeabilized cells, 91% of cells infected with vv-VCPwt are positive for VCP, with an MFI of 160, while 94%
of cells infected with vv-VCPmut are positive, with an MFI of 125. (C) BSC-1 cells were infected overnight at an MOI of 1 with the indicated
viruses. Cells were treated with (permeabilized) or without (nonpermeabilized) 0.1% Triton X-100 and stained for VCP with MAb 3F11 (10
g/ml). The expression of VCP was examined using IF.
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A56, but not K2, is required for the cell surface expression
of VCP. After finding that VCP is expressed on the surfaces of
infected cells independently of HSPGs, we were interested in
identifying potential binding partners of VCP. When a plasmid
encoding the VCP gene under a constitutive promoter was
transfected into uninfected cells, VCP was expressed but could
not be detected on the cell surface (data not shown), suggest-
ing that the surface expression of VCP requires an additional
viral protein(s). To find the binding partner of VCP, we
screened a panel of VACVs with deletions in genes that en-
code various viral transmembrane proteins. We found that
VCP does not localize to the surfaces of cells infected with a
virus that lacks the gene encoding the VACV protein A56
(vv-A56ko) (Fig. 3A). Using confocal microscopy, we also
found that A56 and VCP colocalize on the surfaces of infected
cells (Fig. 3B). Importantly, all of the VCP on the cell surface
colocalizes with A56 (Fig. 3B, merged image). However, the
presence of some green staining in the merged image indicates
that not all of the A56 is bound to VCP. A56 forms a complex
with another VACV protein, K2, and this complex localizes to
the surfaces of infected cells and inhibits infected-cell–cell
fusion (5, 40). A56 is necessary for the surface localization of
K2 (5), raising the possibility that the surface expression of
VCP is dependent on its association with K2 and not A56. To
address this possibility, we used IF to examine the localization
of VCP in the absence of K2. When cells were infected with
vv-VCPwt or vv-K2ko, VCP was expressed on the surface, as
shown by the staining of nonpermeabilized cells (Fig. 3A). This
indicates that the expression of VCP on the cell surface is
dependent on A56 but not K2.
VCP interacts directly with A56. Although the preceding
data suggest that A56 is necessary for the localization of VCP
to the cell surface, it does not provide evidence of a specific
interaction between VCP and A56. When lysates from cells
infected with vv-VCPwt were resolved under nonreducing,
nondenaturing (native) conditions and probed for VCP, three
distinct bands were present (Fig. 4A). These bands include an
30-kDa band representing the VCP monomer, an 50-kDa
band representing the VCP dimer, and a third high-molecular-
mass band. The presence of the high-molecular-mass band
suggests that VCP interacts with another protein. To deter-
mine if A56 was required for the formation of the high-molec-
ular-mass complex, lysate from cells infected with vv-A56ko
was resolved under native conditions and probed for VCP (Fig.
4A). In the absence of A56, we found the 30-kDa and 50-
kDa bands, representing monomeric VCP and dimeric VCP,
but the high-molecular-mass band was no longer present (Fig.
4A). This suggests that the high-molecular-mass complex does
not form in the absence of A56. Furthermore, when lysates
from cells infected with vv-VCPmut were probed for VCP,
only monomeric VCP was detected, demonstrating the impor-
tance of the unpaired cysteine residue on VCP for dimer for-
FIG. 3. The cell surface expression of VCP requires A56 but not K2. (A) RK-13 cells were infected with the indicated viruses overnight at an
MOI of 1, and VCP expression (red) on the surfaces of nonpermeabilized cells and within permeabilized cells was analyzed using IF as described
in the text. Nuclei were counterstained with DAPI (blue). (B) RK-13 cells were infected with vv-VCPwt and surface stained for VCP (red) and
A56 (green). Images were merged to examine the colocalization of A56 and VCP (yellow). , anti.
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mation, as well as the formation of the higher-molecular-mass
complex (Fig. 4A).
To determine if VCP and A56 interact in infected cells, we
used viruses encoding His-tagged forms of VCP (vv-VCPwt-
His) or VCPmut (vv-VCPmut-His) to attempt to pull down
A56. Lysates from cells infected with vv-VCPwt-His or vv-
VCPmut-His were run over nickel-agarose columns. Following
extensive washing, proteins were eluted with imidazole, sepa-
rated using SDS-PAGE, and probed for A56 (Fig. 4B). We
found that A56 was present only in eluates from vv-VCPwt-
His-infected cells, not vv-VCPmut-His-infected cells (Fig. 4B),
indicating that A56 interacts with vv-VCPwt-His but not vv-
VCPmut-His. Taken together, these results indicate that VCP
and A56 interact in infected cells. Of note, Wagenaar and
Moss recently used tandem affinity purification and mass spec-
trometry to identify proteins that interact with A56 (45). Their
study identified VCP as one of many proteins that copurifies
with A56, lending support to our finding that these two pro-
teins interact.
The expression of VCP on the cell surface protects infected
cells from complement-mediated lysis. Activation of comple-
ment can result in the lysis of virus-infected cells (4, 8, 10).
Furthermore, it has been shown that VCP engineered to con-
tain a transmembrane domain is capable of protecting unin-
fected cells from complement-mediated lysis (32). Thus, we
sought to determine if VCP that is naturally expressed on the
surface protects infected cells from complement (Fig. 5). For
these experiments, we used L929 cells since they are known to
be susceptible to lysis by guinea pig complement serum. Prior
to the treatment of infected cells with a polyclonal rabbit anti-
VACV antibody and 25% guinea pig complement serum, cells
were washed to remove secreted VCP in order to examine only
the effect of surface-bound VCP. Following treatment with
complement, the viability of infected cells was assessed using
an amine-reactive viability dye (31). This dye binds to amine
groups on the surfaces of cells but also penetrates damaged
cell membranes and reacts with amine groups in the cytoplasm,
resulting in an increase in the fluorescence intensity of dam-
aged cells (31). We found that treatment of vv-VCPwt infected
cells with antibody and complement resulted in 7% 	 0.7%
more positive cells than treatment with antibody alone. How-
ever, treatment of vv-VCPko- and vv-VCPmut-infected cells
resulted in 32% 	 4% and 23% 	 4%, respectively, more
positive cells than treatment with antibody alone (Fig. 5). Thus,
the presence of VCP on the surfaces of infected cells decreased
cell lysis approximately fourfold. This level of protection is
similar to the level of protection provided by VCP that has
been engineered for membrane expression (32). Complement-
mediated lysis of infected cells was prevented when comple-
ment activation was inhibited with EDTA or when classical
pathway activation was inhibited with EGTA containing Mg2,
indicating that cell lysis was due to classical-pathway activation
(data not shown).
FIG. 4. VCP and A56 interact under native conditions. (A) BSC-1
cells were infected overnight with the indicated virus at an MOI of 5.
Infected cells were then harvested and washed with and lysed in RIPA
buffer. Lysates were run on a 10% precast gel under native (nonre-
ducing, nondenaturing) conditions. Membranes were transferred to
nitrocellulose and probed for VCP using MAb 5F1 (5 g/ml).
(B) BSC-1 cells were infected for 48 h with the indicated viruses
expressing His-tagged versions of VCP at an MOI of 5. Lysates were
run through a nickel-agarose column. Proteins were eluted with 500
mM imidazole; separated on a 10% precast gel under reducing, dena-
turing conditions; and probed for the presence of A56 using a rabbit
polyclonal antibody (top) or an anti-His antibody (bottom). Molecular
mass markers (in kDa) are indicated along the left-hand side of the
gels. , anti.
FIG. 5. Surface-bound VCP protects infected cells from comple-
ment-mediated lysis. L929 cells infected overnight with the indicated
viruses were washed, lifted with PBS–0.5 mM EDTA, and counted.
Cells (5  105) were incubated with 50 g/ml of the IgG fraction of a
polyclonal rabbit anti-VACV antibody (Virostat), washed, and incu-
bated in the presence or absence of 25% guinea pig complement serum
(Sigma) for 45 min at 37°C. Cell lysis was assessed using flow cytometry
by measuring the uptake of an amine-reactive viability dye by damaged
cells. The percentage of positive (lysed) cells was determined using
Overton subtraction. Results are representative of several independent
experiments. Error bars are 	 the standard error of the mean. Statis-
tical significance was determined using Student’s t test. NS, not signif-
icant.
VOL. 82, 2008 EXPRESSION OF VCP ON VACCINIA VIRUS-INFECTED CELLS 4211
DISCUSSION
Prior studies have characterized VCP as the major protein
secreted from VACV-infected cells (17, 18). In addition, stud-
ies with recombinant VCP have demonstrated that VCP is able
to associate with the surfaces of uninfected cells (38). How-
ever, the ability of VCP to bind to the surfaces of VACV-
infected cells has not been examined. In this study, we show
that VCP is expressed on the surfaces of infected cells and
examine the mechanism by which surface localization occurs.
The ability of recombinant VCP to associate with the cell
surface has been attributed to the presence of four putative
heparin binding sites that could allow VCP to interact with
heparin or heparin-like molecules on the cell surface (38).
Thus, when we initially observed VCP staining on the surfaces
of infected cells using IF (Fig. 1A), we assumed that the sur-
face staining was due to secreted VCP binding back to the cell
surface. Several observations led us to question this assump-
tion. First, we noted that when monolayers of cells were in-
fected at an MOI low enough to create plaques but to leave
most cells of the monolayer uninfected, VCP was detected only
on the surfaces of infected cells within the plaques and not on
adjacent uninfected cells. This led us to examine the surface
staining of VCP on uninfected cells after adding recombinant
VCP or concentrated supernatant containing VCP harvested
from infected cells. Neither of these approaches resulted in
detectable surface staining using IF. In order to rule out the
possibility that our observation was due to soluble VCP bind-
ing back to the surfaces of infected cells, we first infected cells
with a VCPko virus and then added recombinant VCP or
concentrated supernatant containing VCP to these cells.
Again, we were unable to detect VCP on the surfaces of these
cells. These findings led us to compare levels of expression of
VCP on the surfaces of wild-type (L929) and HSPG-deficient
(Gro2C) cell lines. We found that the levels of surface expres-
sion of VCP were similar on both cell lines (Fig. 1B). Further-
more, incubating infected cells with soluble heparin did not
diminish the surface staining of VCP. Taken together, these
results indicate that the localization of VCP to the cell surface
during infection can occur independently of HSPGs. The ap-
parent discrepancy between our findings and that of Smith et
al. (38) may be due the fact that we studied VACV-infected
cells and they used an uninfected human umbilical cord vas-
cular endothelial cell line. In addition, they employed FITC-
labeled recombinant VCP to detect surface staining, and this
may have allowed them to detect a lower level of binding than
we were able to detect using antibodies.
Since the attachment of VCP to the infected cell surface
occurred independently of HSPGs and was also not diminished
following the incubation of cells with high-salt buffers, we spec-
ulated that the expression of VCP on the infected-cell surface
was mediated by a covalent interaction or a very high affinity
noncovalent interaction. We hypothesized that the unpaired
N-terminal cysteine residue in VCP might allow this protein to
form a heterodimer with another protein that is expressed on
the cell surface. We found that the expression of VCP on the
cell surface is indeed dependent on this unpaired cysteine
residue (Fig. 2). While this N-terminal cysteine residue is con-
served in the VCP ortholog found in variola virus, SPICE, the
virulent central African strain of monkeypox that expresses a
VCP ortholog, MoPICE, does not contain an unpaired N-
terminal cysteine but instead has an unpaired C-terminal cys-
teine residue (19). The unpaired cysteines on VCP, SPICE,
and MoPICE have been shown to mediate the homodimeriza-
tion of these proteins (19). Given our finding that an unpaired
cysteine residue is necessary for the cell surface localization of
VCP, we suspect that the unpaired cysteines on SPICE and
MoPICE may also mediate the expression of these proteins on
the infected-cell surface.
Our initial hypothesis that the expression of VCP on the cell
surface was mediated by a covalent interaction also led us to
search for a potential binding partner for VCP. VCP was not
expressed on the surfaces of cells transfected with a plasmid
bearing the VCP ORF, suggesting that another viral protein is
necessary for VCP surface expression. By screening a panel of
recombinant VACVs that have various transmembrane pro-
teins genetically deleted, we discovered that the surface ex-
pression of VCP is dependent on the presence of another viral
protein, A56 (Fig. 3A). This finding is supported by a recent
publication by Wagenaar and Moss (45), in which they dem-
onstrated that tandem affinity purification of A56 pulled down
VCP. Although the interaction between the A56-K2 complex
and the VACV entry-fusion complex seems to be dependent
on both A56 and K2 (45), we found that K2 is not required for
the cell surface expression of VCP (Fig. 3A). It is interesting to
note that the ectodomain of A56 contains three cysteine resi-
dues. Although the disulfide bonding pattern of A56 is not
known, the presence of an uneven number of cysteine residues
in the ectodomain and the importance of an unpaired cysteine
residue for the cell surface localization of VCP make it possi-
ble that these proteins form a disulfide-bonded heterodimer.
Analysis of the A56 amino acid sequences from variola virus
and monkeypox virus revealed 92% and 96% identity, respec-
tively, with the VACV A56 protein and conservation of three
cysteine residues in the A56 ectodomain. The high degree of
sequence conservation and the preservation of an uneven num-
ber of cysteine residues in A56 and its orthologs make it in-
teresting to speculate that SPICE and MoPICE may interact
with their cognate A56 proteins using the same mechanism as
VCP’s.
VACV infection results in the production of two morpho-
logically and biology distinct infectious forms (25, 37), mature
virus (MV) and extracellular virus (EV), which differ in their
susceptibilities to complement-mediated neutralization. While
MV is susceptible to neutralization by complement (14, 42),
EV is relatively resistant due to the incorporation of host
cell-derived complement-regulatory proteins into the EV outer
envelope (42). Since A56 is incorporated into the EV envelope
(29, 30) and is not found on MV, it raises the possibility that
VCP is also displayed on EV. If VCP is present on EV, this
may provide additional protection against complement-medi-
ated neutralization. Vanderplasschen et al. examined the abil-
ity of several EV-specific proteins, including A56, to confer
resistance to complement neutralization and found that none
of the proteins examined affected the resistance of EV to
complement (42). However, perhaps in the setting of host
cell-derived complement-regulatory proteins incorporated into
the EV outer envelope, the assays used were not sensitive
enough to measure the contribution of VCP attached to A56.
Given our finding that VCP and A56 interact in infected cells,
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it is possible that VCP is also displayed on EV and provides
additional protection against complement-mediated neutral-
ization. We are currently investigating this possibility.
Our data support a model in which the unpaired cysteine
residue in VCP mediates the cell surface localization of VCP
by allowing VCP and A56 to form a covalently bonded het-
erodimer. However, because mutating the cysteine residue on
VCP disrupts both dimer formation and cell surface attach-
ment, it is possible that the binding of VCP to the cell surface
is dependent on VCP dimer formation. Thus, there are two
possible mechanisms by which VCP could attach to the cell
surface in an HSPG-independent fashion: (i) dimeric VCP
could interact with A56 via a high-affinity interaction or (ii)
monomeric VCP could form a disulfide-linked heterodimer
with A56. We favor a model where VCP interacts with A56 via
a disulfide bond, rather than by dimerizing and noncovalently
associating with A56. This is based on our observation that the
high-molecular-mass band indicative of VCP bound to A56 is
still present when cell lysates are run under nonreducing, but
denaturing, conditions. Further mutagenesis studies of VCP
and A56 will be necessary to better define the interaction
between these two proteins.
The secretion of large amounts of VCP by infected cells has
led to the assumption that soluble VCP protects the site of
infection, including infected cells, from attack by complement.
The present study shows that the expression of VCP on the
surfaces of infected cells could provide infected cells with ad-
ditional protection against complement. Of note, Rosengard et
al. have shown that when VCP is engineered to contain a
transmembrane domain that allows it to be expressed on the
cell surface, it is capable of protecting cells from complement-
mediated lysis (32). They demonstrate a threefold decrease in
lysis in the presence of VCP, which is similar to what we
observed using infected cells.
The ability of VCP to bind to the surfaces of infected cells
and protect them from complement-mediated lysis represents
an important additional function of this protein. By preventing
or delaying the lysis of infected cells, surface-bound VCP could
prolong the production of virus and increase viral titers. Fur-
thermore, limiting complement activation on the surfaces of
cells could also reduce the production of the proinflammatory
peptides C3a and C5a, thereby diminishing local inflammation
and immune system activation. Future studies will determine
the role of surface-bound VCP in poxvirus pathogenesis and
immune responses to VACV-based vaccines. Examining the
role of surface-bound VCP in animal models is complicated by
the fact that the unpaired cysteine residue on VCP mediates
both dimerization and cell surface attachment. In order to fully
define the roles of surface-bound and dimeric VCP in poxvirus
pathogenesis, it will be necessary to separate these two func-
tions. Detailed molecular studies of the interaction between
VCP and A56 may define mutations in A56 that abrogate the
surface expression of VCP without affecting the other func-
tions of A56 and thus allow us to delineate the roles of dimeric
and surface-bound VCP in poxvirus pathogenesis.
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